MSN Labs Launches Semabest: Generic Semaglutide in India

MSN Laboratories has officially launched Semabest, its generic semaglutide, in the Indian domestic market following approval from the Central Drugs Standard Control Organisation (CDSCO). This development marks a significant step toward making GLP-1 receptor agonist therapies more accessible for diabetes management and metabolic health in India.

What is Semabest and How Does Semaglutide Work?

Semabest is MSN Laboratories' generic version of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk as Ozempic for type 2 diabetes and Wegovy for weight management. Semaglutide mimics the GLP-1 hormone, which is naturally released in the gut after eating. It works by:

• Stimulating insulin secretion in a glucose-dependent manner to lower blood sugar.
• Suppressing glucagon release, reducing liver glucose production.
• Slowing gastric emptying to promote satiety and aid weight loss.
• Offering cardiovascular benefits observed in large-scale trials like SUSTAIN.

The therapy is delivered via a pre-filled pen for subcutaneous administration, making it user-friendly for patients managing type 2 diabetes.

Launch Details and Company Statement

Hyderabad-based MSN Laboratories announced the launch in a release, highlighting Semabest's role in affordable metabolic care. "The launch of SEMABEST marks a defining step in our journey to make next-generation metabolic therapies more accessible and affordable. As the burden of diabetes continues to rise, we remain focused on delivering high-quality, innovative solutions that can make a meaningful difference in patients' lives," said MSN Reddy, Founder & CMD, MSN Laboratories.

This launch, published on April 15, 2026, positions Semabest as a direct response to the growing need for cost-effective GLP-1 options in India.

Pricing: Up to 50% Lower Than Innovator Drug

One of the standout features of Semabest is its affordability. The company states it is priced at nearly 50 percent lower than the innovator drug. Specific MRPs include:

• ₹3990 for 2mg
• ₹4490 for 4mg
• ₹5490 for 8mg

These prices make weekly semaglutide injections viable for more patients, especially in a market where out-of-pocket healthcare expenses are common. Compared to branded semaglutide, which can exceed ₹8,000-₹10,000 per dose equivalent in India, Semabest significantly reduces the financial barrier.

Availability and Administration

Semabest is available as a pre-filled pen, simplifying self-administration. Patients typically start at lower doses (e.g., 0.25mg weekly) and titrate up to maintenance levels like 1mg or 2.4mg, under medical supervision.

Clinical Evidence: Bioequivalence and Phase III Data

"The product has demonstrated bioequivalence to the reference (innovator) drug, with its performance further validated through Phase III clinical studies conducted in direct comparison. The results showed comparable reduction in HbA1c levels, along with similar outcomes across key parameters including fasting plasma glucose (FPG), postprandial glucose (PPG) & weight loss. Semabest also exhibited a comparable safety profile," said Kamini Desai, Head - Medical Affairs, MSN Laboratories.

These findings confirm Semabest matches the originator in efficacy for glycemic control and weight management, critical for type 2 diabetes patients. HbA1c reductions of 1-2% are typical with semaglutide, alongside 5-15% body weight loss in clinical use.

The Diabetes Burden in India

India is home to nearly 90 million people living with diabetes, with a significant proportion remaining undiagnosed or inadequately managed. The disease is often associated with serious complications, including cardiovascular disorders, kidney failure, and vision impairment, placing a substantial burden on patients and the healthcare system. Affordable generics like Semabest can help bridge this gap, enabling better adherence and outcomes.

Safety Profile of Semabest and Semaglutide

Semabest's safety mirrors the innovator, with common side effects including nausea, vomiting, diarrhea, and abdominal pain, mostly during dose escalation. Rare risks like pancreatitis, gallbladder issues, or thyroid tumors (from rodent studies) require monitoring. Patients should discuss contraindications (e.g., personal/family history of medullary thyroid carcinoma) with their doctor. Long-term data from trials like LEADER and SUSTAIN show cardiovascular safety.

Who Should Consider Semabest?

Semabest is indicated for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. It's also used for weight management in obese patients with comorbidities. Consult an endocrinologist to assess suitability, especially if on other antidiabetics. Tools like Shotlee can assist in tracking blood glucose, symptoms, and injection schedules for optimal management.

How Semabest Compares to Branded Semaglutide

| Feature | Semabest (MSN) | Ozempic/Wegovy (Novo) | |---------|----------------|-------------------------| | Active Ingredient | Semaglutide | Semaglutide | | Dosing Forms | Pre-filled pen (2mg,4mg,8mg) | Pre-filled pen | | Price | 50% lower (₹3990-5490) | Higher (₹8k+) | | Efficacy | Comparable HbA1c, FPG, PPG, weight loss | Reference standard | | Approval | CDSCO | CDSCO/DCGA |

While bioequivalent, Semabest offers cost savings without compromising quality, ideal for India's price-sensitive market.

Practical Guidance for Patients

Before starting Semabest:

• Get a full diabetes assessment (HbA1c, kidney function).
• Learn proper injection technique (abdomen, thigh, upper arm).
• Monitor for GI side effects; stay hydrated.
• Combine with lifestyle changes for best results.

Regular follow-ups ensure dose optimization. For adherence, apps like Shotlee help log side effects and progress.

Key Takeaways

• MSN Laboratories' Semabest is a CDSCO-approved generic semaglutide launched in India at 50% lower cost.
• Priced ₹3990 (2mg), ₹4490 (4mg), ₹5490 (8mg) in pre-filled pens.
• Phase III data shows bioequivalence in HbA1c reduction, glucose control, weight loss, and safety.
• Aims to tackle India's 90 million diabetes cases and complications.

Conclusion

The launch of Semabest by MSN Laboratories enhances access to proven GLP-1 therapy, potentially transforming diabetes care for millions. Patients should consult healthcare providers to see if it fits their regimen, prioritizing affordability without sacrificing efficacy. Stay informed on metabolic health advancements for better outcomes.